Candida dubliniensis, a new fungal pathogen

Journal of Basic Microbiology

Volumn 42, Issue 3, 2002, Pages 207-227

  Gutierrez J ^a   Morales, P ^a   Gonzalez M A ^a   Quindos G ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; HUMAN IMMUNODEFICIENCY VIRUS;

ANTIFUNGAL AGENT;

CANDIDA; CANDIDIASIS; CLASSIFICATION; DRUG EFFECT; HUMAN; MICROBIOLOGY; OPPORTUNISTIC INFECTION; PATHOGENICITY; REVIEW; VIRULENCE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; HUMANS; OPPORTUNISTIC INFECTIONS; VIRULENCE;

EID: 0035983341     PISSN: 0233111X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4028(200206)42:3<207::AID-JOBM207>3.0.CO;2-C     Document Type: Article

References (118)

1. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance
2. Differentiation of Candida dubliniensis from Candida albicans on Staib agar and caffeic acid-ferric citrate agar
3. Utility of random amplified polymorphic DNA in the discrimination between Candida albicans and Candida dubliniensis
4. First isolation of Candida dubliniensis in Rio grande do sul, Brazil
5. Multiple strains of Candida albicans in the oral cavity of HIV positive and HIV negative patients
6. Genotype identification of Candida dubliniensis isolated from HIV patients by MLEE
7. Genetic characterization of phospholipase C gene from Candida albicans, presence of Homologous sequences in Candida species other than Candida albicans
8. Rapid identification of Candida dubliniensis by indirect immunofluorescence based on differential localization of antigens on C. dubliniensis blastospores and Candida albicans germ tubes
9. Cluster of atypical Candida isolates in a group of Human immunodeficiency virus positive drug users
10. A novel group I intron in C. dubliniensis is homologous to C. albicans intron
11. Candida dubliniensis fungemia, the first four cases in North America
12. Identification of C. dubliniensis in a study of HIV seropositive pediatric dental patients
13. Prevalence of oral lesions by Candida sp., Their varieties and serotypes in a population of patient with AIDS under a Highly active antiretroviral therapy
14. Oral Candida in HIV infection and AIDS, new perspectives new approaches
15. Candidiasis, the emergence of a novel species, Candida dubliniensis
16. Molecular and phenotypic analysis of Candida dubliniensis, a recently identified species linked with oral candidiasis in HIV-infected and AIDS patients
17. Importance of Candida species other than Candida albicans as opportunistic pathogens
18. Candida dubliniensis
19. Molecular characterization by PCR-fingerprinting of C. dubliniensis strains isolated from two HIV-positive patients in Spain
20. Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences
21. Rapid identification of Candida species with species-specific DNA probes
22. DNA fingerprinting patterns of Candida species using HinfI endonuclease
23. Identification of Candida dubliniensis based on temperature and utilization of xylose and alpha-methyl-D-glucoside as determined with the API 20C AUX and Vitek YBC Systems
24. Carbohydrate assimilation profiles of the first Italian Candida dubliniensis clinical isolates recovered from an HIV-infected individual
25. Candida dubliniensis, phylogeny and putative virulence factors
26. Evaluation of the ATB 32 C, automicrobic system and API 20C using clinical yeast isolates
27. Microbiological diagnosis of fungal endocarditis
28. Comparison of virulence factors of oral Candida dubliniensis and Candida albicans isolates in Healthy people and patients with chronic candidosis
29. Rapid identification of Candida albicans, C. glabrata, C. parapsilosis and C. krusei by species-specific PCR of large subunit ribosomal DNA
30. Comparison of the Hydrophobic properties of Candida albicans and Candida dubliniensis
31. Characterization of agglutinin-like sequence genes from non-albicans Candida and phylogenetic analysis of the ALS family
32. Genetic identification of Candida species in HIV-positive patients using the polymerase chain reaction and restriction fragment length polymorphism analysis of its DNA
33. Identification of Candida dubliniensis in a prospective study of patients in the United States
34. Evaluation of a reformulated CHROMagar Candida
35. Cell surface Hydrophobicity-associated adherence of Candida dubliniensis to Human buccal epithelial cells
36. Retrospective identification of Candida dubliniensis among Candida albicans clinical laboratory isolates from HIV and non-HIV individuals
37. Coaggregation of Candida dubliniensis and Candida albicans display surface variation consistent with observed intergeneric coaggregation
38. Coaggregation of Candida dubliniensis with Fusobacterium nucleatum
39. New assay for measuring cell surface hydrophobicities of Candida dubliniensis and Candida albicans
40. Development and characterization of complex DNA fingerprinting probes for the infectious yeast Candida dubliniensis
41. Initial case of Candida dubliniensis infection from Asia, non-mucosal infection
42. Growth competition between Candida dubliniensis and Candida albicans under broth and biofilm growing conditions
43. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar Candida screening and susceptibility testing of isolates
44. Simple, reliable, and cost-effective yeast identification scheme for the clinical laboratory
45. Rapid PCR test for discriminating between Candida albicans and Candida dubliniensis isolates using primers derived from the pH-regulated PHR1 and PHR2 genes of Candida albicans
46. Molecular and phenotypic identification of the yeast pathogen Candida dubliniensis
47. Initial isolation of Candida dubliniensis from the Middle East
48. Development and use of complex probes for DNA fingerprinting the infectious fungi
49. Rapid identification of Candida albicans and other human pathogenic yeast by using short oligonucleotides in a PCR
50. New monoclonal antibody specific for Candida albicans germ tube
51. Candida dubliniensis candidemia in Australia
52. Comparison of C. albicans and C. dubliniensis cell wall mannan and cell surface hydrophobicity
53. Characterization of genetically distinct subgroup of Candida albicans strains isolated from oral cavities of patients infected with human immunodeficiency virus
54. Molecular and phenotypic characterization of genotype Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea
55. Candida dubliniensis candidemia in patients with chemotherapy induced neutropenia and bone marrow transplantation
56. Sequence analysis of a compound coding-region microsatellite in Candida albicans resolves homoplasies and provides a high-resolution tool for genotyping
57. Oral Candida dubliniensis as a clinically important species in HIV-seropositive patients in the United States
58. PCR fingerprinting, a convenient molecular tool to distinguish between Candida dubliniensis and Candida albicans
59. First identification of Candida dubliniensis in the Brest University Hospital (France)
60. Serological differentiation of experimentally induced Candida dubliniensis and Candida albicans infections
61. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis
62. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro
63. Identification of CARE-2 negative Candida albicans isolates as Candida dabliniensis
64. "Room temperature" use of CHROMagar Candida
65. Prevalence of Candida dubliniensis isolates in a yeast stock collection
66. Rapid identification of Candida dubliniensis using a species-specific molecular beacon
67. Differentiation between C. dubliniensis and C. albicans by fatty acid methyl ester analysis using gas liquid chromatography
68. Phagocytosis, oxidative burst, and killing of Candida dubliniensis and Candida albicans by human neutrophils
69. Rapid identification of Candida glabrata by using dipstick to detect trehalase-generated glucose
70. Adherence of Candida albicans strains isolated from AIDS patients. Comparison with pathogenic yeast isolated from patients without infection
71. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents
72. Simple inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans
73. Rapid identification of Candida dubliniensis with commercial yeast identification systems
74. Recovery of Candida dubliniensis from non human immunodeficiency virus infected patients in Israel
75. Emerging pathogens
76. Reverse cross blot Hybridization assay for rapid detection of PCR-amplified DNA from Candida species, Cryptococcus neoformans and Saccharomyces cerevisiae in clinical samples
77. Atypical strains of Candida albicans recovered from AIDS patients
78. Evaluación micológica de un nuevo medio de cultivo cromógeno (Candida ID®) para el aislamiento e identificación presuntiva de Candida albicans y otras levaduras de interés médico
79. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents
80. Candida dubliniensis in radiation-induced oropharyngeal candidiasis
81. Characterization of binding of Candida albicans to small intestinal mucin and its role in adherence to mucosal epithelial cells
82. st isolation in Argentina
83. Azole and echinocandin antifungal agents against Candida species
84. Genotypic relatedness of yeast isolates from women infected with Human immunodeficiency virus and their children
85. Molecular epidemiology of Candida infections in HIV-infected mothers and their offspring
86. Development of simultaneous resistance to fluconazole in Candida albicans and Candida dubliniensis in a patient with AIDS
87. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeast
88. Specific antibodyresponse in a patient with Candida dubliniensis fungemia
89. Distinctive carbohydrate assimilation profiles used to identify the first clinical isolates of C. dubliniensis recovered in the United States
90. Epidemiology of candidemia
91. Mechanism of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporter
92. Isolation of Candida dubliniensis from the oral cavity of an HIV-positive child in Brazil
93. Use of specialized isolation media for recognition and identification of Candida dubliniensis isolates from VIH-infected patients
94. The role of Candida dubliniensis in oral candidiasis in human immunodeficiency vires infected individuals
95. Candida dubliniensis at a cancer center
96. Chlamydospore formation on Staib agar. Observations made before Candida dubliniensis was described
97. A molecular genetic system for the pathogenic yeast Candida dubliniensis
98. Isogenic strain construction and gene targeting in Candida dubliniensis
99. Chlamydospore formation on Staib agar as species-specific characteristic of Candida dubliniensis
100. Oligonucleotide fingerprinting of isolates of Candida species other than Candida albicans and of atypical Candida species from human immunodeficiency virus positive and AIDS patients
101. Candida dubliniensis, characteristics and identification
102. Candida dubliniensis, an emerging opportunist pathogen
103. Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals
104. Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species
105. Candida dubliniensis, An update
106. Candida dubliniensis sp. nov., phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals
107. New PCR primer pairs specific for Candida dubliniensis and detection of the fungi from the Candida albicans clinical isolates in Japan
108. Rapid differentiation of closely related species and strains by pyrolysis-mass spectrometry and Fourier transform-infrared spectroscopy
109. Evaluation of phenotypic markers for selection and identification of Candida dubliniensis
110. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole
111. Presumptive identification of an emerging yeast pathogen, Candida dubliniensis (sp. nov.) reduces 2,3,5-triphenyltetrazolium chloride
112. Paediatric AIDS related linear gingival erythema, a form for erythematous candidiasis?
113. Candida, Cryptococcus, and other yeasts of medical importance
114. Identification of Candida dubliniensis, based on ribosomal DNA sequence analysis
115. Isolation and identification of candida from the oral cavity
116. Isolation of C. dubliniensis from insulin-using diabetes mellitus patients
117. Identification and phylogenetic relationship of the most common pathogenic Candida species inferred from mitochondrial cytochrome b gene sequences